1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
Real-time Estimate Cboe Europe  -  05/27 10:54:11 am EDT
10591.00 GBX   +0.43%
09:22aAstraZeneca Doses First Patients in Phase-III Trial Evaluating Anifrolumab in Kidney Inflammation
MT
09:03aFirst Patients Dosed in IRIS Phase III Trial Evaluating Anifrolumab in Lupus Nephritis
BU
08:18aASTRAZENECA : Berenberg keeps its Buy rating
MD
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

EMA: IN JANUARY 2022, PRAC CONCLUDED THAT TRANSVERSE MYELITIS SHOULD BE ADDED TO THE PRODUCT INFORMATION AS A SIDE EFFECT OF ASTRAZENECA VACCINE

01/20/2022 | 06:49am EDT

EMA: IN JANUARY 2022, PRAC CONCLUDED THAT TRANSVERSE MYELITIS SHOULD BE ADDED TO THE PRODUCT INFORMATION AS A SIDE EFFECT OF ASTRAZENECA VACCINE


© Reuters 2022
All news about ASTRAZENECA PLC
09:22aAstraZeneca Doses First Patients in Phase-III Trial Evaluating Anifrolumab in Kidney In..
MT
09:03aFirst Patients Dosed in IRIS Phase III Trial Evaluating Anifrolumab in Lupus Nephritis
BU
08:18aASTRAZENECA : Berenberg keeps its Buy rating
MD
05/26Cancer treatments may benefit from lessons of pandemic set-backs -AstraZeneca executive
RE
05/25ASTRAZENECA : JP Morgan keeps its Buy rating
MD
05/25French health body backs new COVID vaccine booster campaign for this autumn
RE
05/24Indian vaccine giant Serum plans African plant in global expansion
RE
05/24Danske Bank Initiates Coverage on AstraZeneca With Buy Rating
MT
05/24Vaxzevria approved in the EU as third dose booster against COVID-19
AQ
05/24AstraZeneca aims to transform cancer care with practice-changing data at ASCO 2022
AQ
More news
Analyst Recommendations on ASTRAZENECA PLC
More recommendations
Financials (USD)
Sales 2022 43 665 M - -
Net income 2022 5 151 M - -
Net Debt 2022 23 311 M - -
P/E ratio 2022 40,2x
Yield 2022 2,22%
Capitalization 206 B 206 B -
EV / Sales 2022 5,24x
EV / Sales 2023 4,81x
Nbr of Employees 83 100
Free-Float 96,4%
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 26
Last Close Price 132,74 $
Average target price 143,66 $
Spread / Average Target 8,22%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Aradhana Sarin Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas NICOLAS Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capi. (M$)
ASTRAZENECA PLC21.53%205 677
JOHNSON & JOHNSON4.90%472 231
PFIZER, INC.-8.57%302 932
ROCHE HOLDING AG-12.16%282 336
ELI LILLY AND COMPANY13.48%282 164
ABBVIE INC.11.20%266 074